A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Trial Profile

A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Medivation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results assessing safety data from AFFIRM,PREVAIL,TERRAIN,STRIVE trials (n=3681) presented at the 41st European Society for Medical Oncology Congress.
    • 09 Oct 2016 According to an Astellas Pharma media release, data from this study was presented at the European Society for Medical Oncology Congress (ESMO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top